MA33618B1 - Agent thérapeutique destiné aux troubles de l'humeur - Google Patents

Agent thérapeutique destiné aux troubles de l'humeur

Info

Publication number
MA33618B1
MA33618B1 MA34733A MA34733A MA33618B1 MA 33618 B1 MA33618 B1 MA 33618B1 MA 34733 A MA34733 A MA 34733A MA 34733 A MA34733 A MA 34733A MA 33618 B1 MA33618 B1 MA 33618B1
Authority
MA
Morocco
Prior art keywords
mood disorders
therapeutic agent
therapeutic
analog
pharmaceutically acceptable
Prior art date
Application number
MA34733A
Other languages
Arabic (ar)
English (en)
Inventor
Koji Yamada
Tomoyuki Kanda
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33618(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of MA33618B1 publication Critical patent/MA33618B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un agent thérapeutique et/ou prophylactique destiné aux troubles de l'humeur, qui contient un dérivé de thiazole représenté par la formule générale (i) dans laquelle r1 représente un groupe aryle ou analogue, et r2 représente un groupe pyridyle ou analogue) ou un de ses sels pharmaceutiquement acceptables en tant que principe actif.
MA34733A 2009-09-02 2012-03-30 Agent thérapeutique destiné aux troubles de l'humeur MA33618B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009202893 2009-09-02
PCT/JP2010/064988 WO2011027805A1 (fr) 2009-09-02 2010-09-02 Agent thérapeutique destiné aux troubles de l'humeur

Publications (1)

Publication Number Publication Date
MA33618B1 true MA33618B1 (fr) 2012-09-01

Family

ID=43649339

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34733A MA33618B1 (fr) 2009-09-02 2012-03-30 Agent thérapeutique destiné aux troubles de l'humeur

Country Status (31)

Country Link
US (1) US9249135B2 (fr)
EP (1) EP2474543B1 (fr)
JP (1) JP5663484B2 (fr)
KR (1) KR101762981B1 (fr)
CN (1) CN102482272A (fr)
AU (1) AU2010290423B2 (fr)
BR (1) BR112012004851B8 (fr)
CA (1) CA2772920C (fr)
CL (1) CL2012000534A1 (fr)
CY (1) CY1119118T1 (fr)
DK (1) DK2474543T3 (fr)
DO (1) DOP2012000058A (fr)
EA (1) EA030333B1 (fr)
ES (1) ES2633538T3 (fr)
GE (1) GEP20156224B (fr)
HR (1) HRP20171137T1 (fr)
HU (1) HUE033690T2 (fr)
IL (1) IL218321A (fr)
LT (1) LT2474543T (fr)
MA (1) MA33618B1 (fr)
ME (1) ME02804B (fr)
MX (1) MX2012002528A (fr)
NZ (1) NZ598750A (fr)
PL (1) PL2474543T3 (fr)
PT (1) PT2474543T (fr)
RS (1) RS56345B1 (fr)
SI (1) SI2474543T1 (fr)
TN (1) TN2012000092A1 (fr)
UA (1) UA110097C2 (fr)
WO (1) WO2011027805A1 (fr)
ZA (1) ZA201202346B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) * 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
CN112292183A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑
WO2019244000A1 (fr) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Imidazoles substitués par phényle et pyridinyle utilisés en tant que modulateurs de roryt
WO2019243999A1 (fr) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyrazoles substitués par phényle utilisés en tant que modulateurs de roryt
EP3807261B1 (fr) 2018-06-18 2022-07-13 Janssen Pharmaceutica NV Pyridinyl-pyrazoles utilisés utilisés comme modulateurs de roryt
WO2023201267A1 (fr) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant trop-2

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116967C (fr) 1992-07-08 2003-08-19 Fumio Suzuki Antidepresseurs
DE69834500T2 (de) 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
JP2005516891A (ja) 2001-09-13 2005-06-09 シェーリング　コーポレイション アデノシンＡ２ａレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
MXPA05013148A (es) 2003-06-10 2006-03-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de un trastorno de la ansiedad.
HUE025659T2 (en) 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
EP1730122A2 (fr) 2004-03-30 2006-12-13 Taisho Pharmaceutical Co., Ltd Derives de pyrimidine et procedes de traitement lies a l'utilisation de ceux-ci
JPWO2006137527A1 (ja) * 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
LT1921077T (lt) 2005-08-02 2017-09-25 Kyowa Hakko Kirin Co., Ltd. Agentas, skirtas miego sutrikimo gydymui ir (arba) prevencijai

Also Published As

Publication number Publication date
CN102482272A (zh) 2012-05-30
MX2012002528A (es) 2012-04-11
DK2474543T3 (en) 2017-08-14
EP2474543A4 (fr) 2013-05-29
PT2474543T (pt) 2017-08-03
ZA201202346B (en) 2015-11-25
JPWO2011027805A1 (ja) 2013-02-04
GEP20156224B (en) 2015-01-26
AU2010290423B2 (en) 2015-10-29
LT2474543T (lt) 2017-08-25
BR112012004851B8 (pt) 2021-05-25
JP5663484B2 (ja) 2015-02-04
US20120184554A1 (en) 2012-07-19
IL218321A0 (en) 2012-04-30
HUE033690T2 (hu) 2017-12-28
CA2772920A1 (fr) 2011-10-03
TN2012000092A1 (en) 2013-09-19
BR112012004851B1 (pt) 2021-03-02
PL2474543T3 (pl) 2017-09-29
AU2010290423A1 (en) 2012-04-19
BR112012004851A2 (pt) 2016-04-05
EA201270359A1 (ru) 2012-09-28
RS56345B1 (sr) 2017-12-29
UA110097C2 (uk) 2015-11-25
NZ598750A (en) 2014-08-29
KR101762981B1 (ko) 2017-07-28
SI2474543T1 (sl) 2017-08-31
IL218321A (en) 2016-10-31
CY1119118T1 (el) 2018-02-14
DOP2012000058A (es) 2012-06-30
EA030333B1 (ru) 2018-07-31
HRP20171137T1 (hr) 2017-10-06
US9249135B2 (en) 2016-02-02
CL2012000534A1 (es) 2012-09-14
ES2633538T3 (es) 2017-09-21
EP2474543A1 (fr) 2012-07-11
CA2772920C (fr) 2018-07-31
ME02804B (fr) 2018-01-20
WO2011027805A1 (fr) 2011-03-10
KR20120047310A (ko) 2012-05-11
EP2474543B1 (fr) 2017-05-03

Similar Documents

Publication Publication Date Title
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
ECSP12011880A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
TW200728307A (en) Novel spirochromanone derivatives
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MX2010004232A (es) Compuesto de indolina de pirimidilo.
UY30118A1 (es) Compueto amina trisustituido
NO20090202L (no) Prolylhydroksylaseinhibitorer
BRPI0607308A2 (pt) compostos, composições farmacêuticas e usos dos referidos compostos
EA200700909A1 (ru) Азаиндолкарбоксамиды
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
BRPI0515851A (pt) composto de pirimidona
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA32240B1 (fr) Inhibiteurs de désacétylases b à base d'hydroxamate
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
AR068438A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona
WO2009040314A3 (fr) Nouveaux dérivés de l'acétone substitués par un hétéroaryle, appropriés comme inhibiteurs de la phospholipase a2
AR052413A1 (es) Nuevos derivados de piridotienopiriidina
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
WO2011159124A3 (fr) Nouveau dérivé de benzoxazole présentant une activité inhibitrice contre l'interleukine 6, procédé pour le préparer, et composition pharmaceutique le contenant
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
AR068439A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona